We demonstrated that combinations of MET with anti-PD-1/PD-L1 effectively stimulate an anti-tumor immune response by activating key cytosolic DNA sensors and enhancing pro-immune characteristics, particularly in LKB1 mutant NSCLC tumors. The gene discussed is CD274; the disease is neoplasm.